CoChat

Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background Varenicline tartrate (Champix), a new smoking cessation medicine, was launched in the UK in December 2006. Varenicline is a highly selective partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor (alpha(4)beta(2) receptor). The partial agonistic binding leads to alleviation of symptoms of craving and withdrawal, and simultaneously prevents nicotine from binding to the alpha(4)beta(2) receptor thereby causing reduction in the rewarding and reinforcing effects of smoking. Regulatory concerns have arisen about psychiatric events associated with varenicline, including depression, suicidal ideation and changes in behaviour/emotion.Aim To present the interim results of an ongoing study by the Drug Safety Research Unit (DSRU) monitoring the safety of varenicline.Methods The observational cohort study is being conducted to study the postmarketing safety of varenicline, using modified prescription-event monitoring (PEM) methodology. Patients are identified from dispensed prescriptions issued by general practitioners (GPs) from December 2006. Demographic, clinical event (during the course and 1 month after stopping varenicline, reasons for discontinuing and suspected adverse drug reactions [ADRs] to varenicline) and drug utilization data are collected from detailed study-specific questionnaires posted to GPs at least 4 months after the date of first prescription for each patient. Event incidence densities (IDs; number of first reports of an event/1000 patient-months of exposure) are calculated.Results The interim cohort comprises 2,682 patients: median age 47 years (interquartile range [IQR] 38-56), 60.7% females (n = 1627). Nausea/vomiting was the most frequent clinical reason for stopping varenicline (n = 91; 35.3% of clinical reasons) and the most frequently reported suspected ADR to varenicline (n = 60, 50.9% of patients for whom an ADR was reported). The most frequently reported psychiatric events (causality not implied) during treatment included (n; % of cohort): sleep disorder (43; 1.6%), anxiety (33; 1.2%), depression (29; 1.1%), abnormal dreams (26; 1.0%) and mood change (17; 0.6%). Two cases of attempted suicide were reported during treatment with varenicline (one patient took an overdose of a benzodiazepine with alcohol, the other slashed their wrist). Both these patients had previous history of psychiatric illness and precipitating factors for the event.Conclusion This study reflects 'real life' use of varenicline. Nausea/vomiting - the event most frequently reported as an ADR and as reason for stopping treatment - is listed in the UK Summary of Product Characteristics (SPC). The most frequently reported psychiatric events are listed in the UK SPC. All patients with suicidal events either had a past medical history of psychiatric illness prior to starting varenicline and/or a precipitating factor for the event. Clinicians should closely monitor patients with pre-existing psychiatric illness who are taking varenicline. Further evaluation of events of interest including psychiatric events is ongoing. Results presented are expected to change as the cohort size increases. Results of this study should be taken into account together with other clinical and pharmacoepidemiological studies.

Overview

Integrity signals

Registry

Crossref · 10.2165/00002018-200932060-00006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 6 references

Cited by

See all 71

Metadata

Authors
Kasliwal, R., Wilton, L. V., & Shakir, S. A. W.
Affiliations
Drug Safety Research Unit (GB)
Corresponding author
Kasliwal, Rachna
Venue
Drug Safety
Published
2009-05
Volume
32
Issue
6
Pages
499-507
ISSN
0114-5916 (ISSN-L)
OpenAlex
W187469247
Cited by
71
References
6
Citations by year
2024: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 4 · 2013: 9 · 2012: 6
FWCI
14.78
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Portsmouth
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
varenicline, smoking cessation, post-marketing safety, adverse drug reactions, psychiatric adverse events, depression, suicidal ideation, medication use, prescription-event monitoring, general practice, nicotine receptor partial agonist, nausea and vomiting, drug discontinuation, England, United Kingdom, pharmacoepidemiology, sleep disorders, mood changes
MeSH terms
Varenicline, Adult, Benzazepines, Drug Utilization, England, Family Practice, Female, Humans, Male, Middle Aged, Drug Prescriptions, Quinoxalines, Safety, Smoking Cessation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study. https://app.cochat.ai/papers/10.2165/00002018-200932060-00006
The paper
Kasliwal, R., Wilton, L. V., & Shakir, S. A. W. (2009). Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study. Drug Safety. https://doi.org/10.2165/00002018-200932060-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.